21 results on '"Kennedy, Sara M."'
Search Results
2. Pharmacotherapy for Alcohol Use Disorder: A Systematic Review and Meta-Analysis.
- Author
-
McPheeters, Melissa, O'Connor, Elizabeth A., Riley, Sean, Kennedy, Sara M., Voisin, Christiane, Kuznacic, Kaitlin, Coffey, Cory P., Edlund, Mark D., Bobashev, Georgiy, and Jonas, Daniel E.
- Subjects
ALCOHOLISM ,TRAFFIC accidents ,ALCOHOL drinking ,DRUG therapy ,CINAHL database - Abstract
Key Points: Question: Which pharmacotherapies are associated with improved outcomes for people with alcohol use disorder? Findings: In this systematic review and meta-analysis that included 118 clinical trials and 20 976 participants, 50 mg/d of oral naltrexone and acamprosate were each associated with significantly improved alcohol consumption-related outcomes compared with placebo. Meaning: These findings support oral naltrexone at 50 mg/d and acamprosate as first-line therapies for alcohol use disorder. Importance: Alcohol use disorder affects more than 28.3 million people in the United States and is associated with increased rates of morbidity and mortality. Objective: To compare efficacy and comparative efficacy of therapies for alcohol use disorder. Data Sources: PubMed, the Cochrane Library, the Cochrane Central Trials Registry, PsycINFO, CINAHL, and EMBASE were searched from November 2012 to September 9, 2022 Literature was subsequently systematically monitored to identify relevant articles up to August 14, 2023, and the PubMed search was updated on August 14, 2023. Study Selection: For efficacy outcomes, randomized clinical trials of at least 12 weeks' duration were included. For adverse effects, randomized clinical trials and prospective cohort studies that compared drug therapies and reported health outcomes or harms were included. Data Extraction and Synthesis: Two reviewers evaluated each study, assessed risk of bias, and graded strength of evidence. Meta-analyses used random-effects models. Numbers needed to treat were calculated for medications with at least moderate strength of evidence for benefit. Main Outcomes and Measures: The primary outcome was alcohol consumption. Secondary outcomes were motor vehicle crashes, injuries, quality of life, function, mortality, and harms. Results: Data from 118 clinical trials and 20 976 participants were included. The numbers needed to treat to prevent 1 person from returning to any drinking were 11 (95% CI, 1-32) for acamprosate and 18 (95% CI, 4-32) for oral naltrexone at a dose of 50 mg/d. Compared with placebo, oral naltrexone (50 mg/d) was associated with lower rates of return to heavy drinking, with a number needed to treat of 11 (95% CI, 5-41). Injectable naltrexone was associated with fewer drinking days over the 30-day treatment period (weighted mean difference, −4.99 days; 95% CI, −9.49 to −0.49 days) Adverse effects included higher gastrointestinal distress for acamprosate (diarrhea: risk ratio, 1.58; 95% CI, 1.27-1.97) and naltrexone (nausea: risk ratio, 1.73; 95% CI, 1.51-1.98; vomiting: risk ratio, 1.53; 95% CI, 1.23-1.91) compared with placebo. Conclusions and Relevance: In conjunction with psychosocial interventions, these findings support the use of oral naltrexone at 50 mg/d and acamprosate as first-line pharmacotherapies for alcohol use disorder. This systematic review and meta-analysis evaluates efficacy and comparative efficacy of 9 therapies for alcohol use disorder (AUD). [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
3. Not Just Cigarettes : A More Comprehensive Look at Marijuana and Tobacco Use Among African American and White Youth and Young Adults
- Author
-
Kennedy, Sara M., Caraballo, Ralph S., Rolle, Italia V., and Rock, Valerie J.
- Published
- 2016
4. National Surveys and Tobacco Use Among African Americans : A Review of Critical Factors
- Author
-
Rolle, Italia V., Beasley, Derrick D., Kennedy, Sara M., Rock, Valerie J., and Neff, Linda
- Published
- 2016
5. Tobacco and Marijuana Initiation Among African American and White Young Adults
- Author
-
Kennedy, Sara M., Patel, Roshni P., Cheh, Paul, Hsia, Jason, and Rolle, Italia V.
- Published
- 2016
6. Cigarette Smoking Among Inmates by Race/Ethnicity : Impact of Excluding African American Young Adult Men From National Prevalence Estimates
- Author
-
Kennedy, Sara M., Sharapova, Saida R., Beasley, Derrick D., and Hsia, Jason
- Published
- 2016
7. Cigarette, Cigar, and Marijuana Use Among High School Students — United States, 1997–2013
- Author
-
Rolle, Italia V., Kennedy, Sara M., Agaku, Israel, Jones, Sherry Everett, Bunnell, Rebecca, Caraballo, Ralph, Xu, Xin, Schauer, Gillian, and McAfee, Tim
- Published
- 2015
8. Interventions to prevent iatrogenic anemia: a Laboratory Medicine Best Practices systematic review
- Author
-
Whitehead, Nedra S., Williams, Laurina O., Meleth, Sreelatha, Kennedy, Sara M., Ubaka-Blackmoore, Nneka, Geaghan, Sharon M., Nichols, James H., Carroll, Patrick, McEvoy, Michael T., Gayken, Julie, Ernst, Dennis J., Litwin, Christine, Epner, Paul, Taylor, Jennifer, and Graber, Mark L.
- Published
- 2019
- Full Text
- View/download PDF
9. Smoke-Free Policies in U.S. Prisons and Jails : A Review of the Literature
- Author
-
Kennedy, Sara M., Davis, Shane P., and Thorne, Stacy L.
- Published
- 2015
10. Clinical interventions to reduce secondhand smoke exposure among pregnant women: a systematic review
- Author
-
Tong, Van T, Dietz, Patricia M, Rolle, Italia V, Kennedy, Sara M, Thomas, William, and England, Lucinda J
- Published
- 2015
11. Tobacco Use Among Middle and High School Students — United States, 2013
- Author
-
Arrazola, René A., Neff, Linda J., Kennedy, Sara M., Holder-Hayes, Enver, and Jones, Christopher D.
- Published
- 2014
12. Screening for Depression and Suicide Risk in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
- Author
-
Viswanathan, Meera, Wallace, Ina F., Cook Middleton, Jennifer, Kennedy, Sara M., McKeeman, Joni, Hudson, Kesha, Rains, Caroline, Vander Schaaf, Emily B., and Kahwati, Leila
- Subjects
DIAGNOSIS of mental depression ,RESEARCH ,SUICIDE prevention ,RESEARCH methodology ,SYSTEMATIC reviews ,MEDICAL screening ,EVALUATION research ,PREVENTIVE health services ,COMPARATIVE studies ,MENTAL depression ,POLICY sciences - Abstract
Importance: Depression, suicidal ideation, and self-harm behaviors in youth are associated with functional impairment and suicide.Objective: To review the evidence on screening for depression or suicide risk in children and adolescents to inform the US Preventive Services Task Force (USPSTF).Data Sources: PubMed, Cochrane Library, PsycINFO, CINAHL, and trial registries through July 19, 2021; references, experts, and surveillance through June 1, 2022.Study Selection: English-language, randomized clinical trials (RCTs) of screening for depression or suicide risk; diagnostic test accuracy studies; RCTs of psychotherapy and first-line pharmacotherapy; RCTs, observational studies, and systematic reviews reporting harms.Data Extraction and Synthesis: Two reviewers assessed titles/abstracts, full-text articles, and study quality and extracted data; when at least 3 similar studies were available, meta-analyses were conducted.Main Outcomes and Measures: Test accuracy, symptoms, response, remission, loss of diagnosis, mortality, functioning, suicide-related events, and adverse events.Results: Twenty-one studies (N = 5433) were included for depression and 19 studies (N = 6290) for suicide risk. For depression, no studies reported on the direct effects of screening on health outcomes, and 7 studies (n = 3281) reported sensitivity of screening instruments ranging from 0.59 to 0.94 and specificity from 0.38 to 0.96. Depression treatment with psychotherapy was associated with improved symptoms (Beck Depression Inventory pooled standardized mean difference, -0.58 [95% CI, -0.83 to -0.34]; n = 471; 4 studies; and Hamilton Depression Scale pooled mean difference, -2.25 [95% CI, -4.09 to -0.41]; n = 262; 3 studies) clinical response (3 studies with statistically significant results using varying thresholds), and loss of diagnosis (relative risk, 1.73 [95% CI, 1.00 to 3.00; n = 395; 4 studies). Pharmacotherapy was associated with improvement on symptoms (Children's Depression Rating Scale-Revised mean difference, -3.76 [95% CI, -5.95 to -1.57; n = 793; 3 studies), remission (relative risk, 1.20 [95% CI, 1.00 to 1.45]; n = 793; 3 studies) and functioning (Children's Global Assessment Scale pooled mean difference, 2.60 (95% CI, 0.78 to 4.42; n = 793; 3 studies). Other outcomes were not statistically significantly different. Differences in suicide-related outcomes and adverse events for pharmacotherapy when compared with placebo were not statistically significant. For suicide risk, no studies reported on the direct benefits of screening on health outcomes, and 2 RCTs (n = 2675) reported no harms of screening. One study (n = 581) reported on sensitivity of screening, ranging from 0.87 to 0.91; specificity was 0.60. Sixteen RCTs (n = 3034) reported on suicide risk interventions. Interventions were associated with lower scores for the Beck Hopelessness Scale (pooled mean difference, -2.35 [95% CI, -4.06 to -0.65]; n = 644; 4 RCTs). Findings for other suicide-related outcomes were mixed or not statistically significantly different.Conclusion and Relevance: Indirect evidence suggested that some screening instruments were reasonably accurate for detecting depression. Psychotherapy and pharmacotherapy were associated with some benefits and no statistically significant harms for depression, but the evidence was limited for suicide risk screening instruments and interventions. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
13. Screening for Anxiety in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force.
- Author
-
Viswanathan, Meera, Wallace, Ina F., Cook Middleton, Jennifer, Kennedy, Sara M., McKeeman, Joni, Hudson, Kesha, Rains, Caroline, Vander Schaaf, Emily B., and Kahwati, Leila
- Subjects
ANXIETY disorders treatment ,RESEARCH ,RESEARCH methodology ,SYSTEMATIC reviews ,MEDICAL screening ,EVALUATION research ,COMPARATIVE studies ,ANXIETY ,POLICY sciences ,ANXIETY disorders ,SERTRALINE - Abstract
Importance: Anxiety in children and adolescents is associated with impaired functioning, educational underachievement, and future mental health conditions.Objective: To review the evidence on screening for anxiety in children and adolescents to inform the US Preventive Services Task Force.Data Sources: PubMed, Cochrane Library, PsycINFO, CINAHL, and trial registries through July 19, 2021; references, experts, and surveillance through June 1, 2022.Study Selection: English-language, randomized clinical trials (RCTs) of screening; diagnostic test accuracy studies; RCTs of cognitive behavioral therapy (CBT) or US Food and Drug Administration-approved pharmacotherapy; RCTs, observational studies, and systematic reviews reporting harms.Data Extraction and Synthesis: Two reviewers assessed titles/abstracts, full-text articles, and study quality and extracted data; when at least 3 similar studies were available, meta-analyses were conducted.Main Outcomes and Measures: Test accuracy, symptoms, response, remission, loss of diagnosis, all-cause mortality, functioning, suicide-related symptoms or events, adverse events.Results: Thirty-nine studies (N = 6065) were included. No study reported on the direct benefits or harms of screening on health outcomes. Ten studies (n = 3260) reported the sensitivity of screening instruments, ranging from 0.34 to 1.00, with specificity ranging from 0.47 to 0.99. Twenty-nine RCTs (n = 2805) reported on treatment: 22 on CBT, 6 on pharmacotherapy, and 1 on CBT, sertraline, and CBT plus sertraline. CBT was associated with gains on several pooled measures of symptom improvement (magnitude of change varied by outcome measure), response (pooled relative risk [RR], 1.89 [95% CI, 1.17 to 3.05]; n = 606; 6 studies), remission (RR, 2.68 [95% CI, 1.48 to 4.88]; n = 321; 4 studies), and loss of diagnosis (RR range, 3.02-3.09) when compared with usual care or wait-list controls. The evidence on functioning for CBT was mixed. Pharmacotherapy, when compared with placebo, was associated with gains on 2 pooled measures of symptom improvement-mean difference (Pediatric Anxiety Rating Scale mean difference, -4.0 [95% CI, -5.5 to -2.5]; n = 726; 5 studies; and Clinical Global Impression-Severity scale mean difference, -0.84 [95% CI, -1.13 to -0.55]; n = 550; 4 studies) and response (RR, 2.11 [95% CI, 1.58 to 2.98]; n = 370; 5 studies)-but was mixed on measures of functioning. Eleven RCTs (n = 1293) reported harms of anxiety treatments. Suicide-related harms were rare, and the differences were not statistically significantly different.Conclusions and Relevance: Indirect evidence suggested that some screening instruments were reasonably accurate. CBT and pharmacotherapy were associated with benefits; no statistically significant association with harms was reported. [ABSTRACT FROM AUTHOR]- Published
- 2022
- Full Text
- View/download PDF
14. Evaluating Intensity, Complexity, and Potential for Causal Inference in Social Needs Interventions: A Review of a Scoping Review.
- Author
-
Viswanathan, Meera, Kennedy, Sara M., Sathe, Nila, Eder, Michelle L., Ng, Valerie, Kugley, Shannon, Lewis, Megan A., and Gottlieb, Laura M.
- Published
- 2024
- Full Text
- View/download PDF
15. Screening for Hypertension in Children and Adolescents: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force.
- Author
-
Gartlehner, Gerald, Vander Schaaf, Emily B., Orr, Colin, Kennedy, Sara M., Clark, Rachel, and Viswanathan, Meera
- Subjects
CARDIOVASCULAR disease prevention ,HYPERTENSION ,ANTIHYPERTENSIVE agents ,SYSTEMATIC reviews ,MEDICAL screening ,MEDICAL protocols ,PREVENTIVE health services ,EXERCISE ,COMBINED modality therapy ,BLOOD pressure measurement - Abstract
Importance: Childhood hypertension can result in adverse outcomes during adulthood; identifying and treating primary and secondary childhood hypertension may reduce such risks.Objective: To update the evidence on screening and treatment of hypertension in childhood and adolescence for the US Preventive Services Task Force.Data Sources: PubMed, Cochrane Library, International Pharmaceutical Abstracts, EMBASE, and trial registries through September 3, 2019; bibliographies from retrieved articles, experts, and surveillance of the literature through October 6, 2020.Study Selection: Fair- or good-quality English-language studies evaluating diagnostic accuracy of blood pressure screening; cohort studies assessing the association of hypertension in childhood and adolescence with blood pressure or other intermediate outcomes in adulthood; randomized clinical trials (RCTs) or meta-analyses of pharmacological and lifestyle interventions.Data Extraction and Synthesis: Two reviewers independently assessed titles/abstracts and full-text articles, extracted data, and assessed study quality; the evidence was synthesized qualitatively.Main Outcomes and Measures: Sensitivity, specificity, and measures of association between childhood and adulthood blood pressure; reduction of childhood blood pressure; adverse effects of treatments.Results: Forty-two studies from 43 publications were included (N>12 400). No studies evaluated the benefits or harms of screening and the effect of treating childhood hypertension on outcomes in adulthood. One study reported a sensitivity of 0.82 and a specificity of 0.70 for 2 office-based blood pressure measurements. Twenty observational studies suggested a significant association between childhood hypertension and abnormal blood pressure in adulthood (odds ratios, 1.1-4.5; risk ratios, 1.45-3.60; hazard ratios, 2.8-3.2). Thirteen placebo-controlled RCTs and 1 meta-analysis assessed reductions in systolic (SBP) and diastolic blood pressure from pharmacological treatments. Pooled reductions of SBP were -4.38 mm Hg (95% CI, -7.27 to -2.16) for angiotensin-converting enzyme inhibitors and -3.07 mm Hg (95% CI, -4.99 to -1.44) for angiotensin receptor blockers. Candesartan reduced SBP by -6.56 mm Hg (P < .001; n = 240). β-Blockers, calcium channel blockers, and mineralocorticoid receptor antagonists did not achieve significant reductions over 2 to 4 weeks. SBP was significantly reduced by exercise over 8 months (-4.9 mm Hg, P ≤ .05; n = 69), by dietary approaches to stop hypertension over 3 months (-2.2 mm Hg, P < .01; n = 57), and by a combination of drug treatment and lifestyle interventions over 6 months (-7.6 mm Hg; P < .001; n = 95). Low-salt diet did not achieve reductions of blood pressure.Conclusions and Relevance: Observational studies indicate an association between hypertension in childhood and hypertension in adulthood. However, the evidence is inconclusive whether the diagnostic accuracy of blood pressure measurements is adequate for screening asymptomatic children and adolescents in primary care. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
16. Racial Health Equity and Social Needs Interventions: A Review of a Scoping Review.
- Author
-
Cené, Crystal W., Viswanathan, Meera, Fichtenberg, Caroline M., Sathe, Nila A., Kennedy, Sara M., Gottlieb, Laura M., Cartier, Yuri, and Peek, Monica E.
- Published
- 2023
- Full Text
- View/download PDF
17. Modes of ever marijuana use among adult tobacco users and non-tobacco users— Styles 2014.
- Author
-
Singh, Tushar, Kennedy, Sara M., Sharapova, Saida S., Schauer, Gillian L., and V. Rolle, Italia
- Subjects
SMOKING ,CANNABIS (Genus) ,CONFIDENCE intervals ,PROBABILITY theory ,RESEARCH funding ,TOBACCO ,SECONDARY analysis ,SOCIOECONOMIC factors ,EQUIPMENT & supplies ,ELECTRONIC cigarettes ,DATA analysis software ,DESCRIPTIVE statistics ,ODDS ratio - Abstract
Background: Tobacco and marijuana use are related behaviors; therefore, it is important to identify how users consume marijuana, and how it varies with tobacco use status. We estimated the modes of ever marijuana use among current, former, and never adult tobacco users. Methods: Weighted data were analyzed for 4181 adults from 2014Styles, an online consumer panel survey of US adults, to estimate proportions for modes of ever marijuana use. Differences in modes of ever marijuana use between categories of tobacco use status were assessed (p-value <0.05). Results: More than half of current (56.6%) and former tobacco users (50.9%) had ever used marijuana, whereas only 13.0% of never tobacco users had ever used marijuana. Among ever marijuana users, joint use was the most common mode of use among current (86.4%), former (92.5%), and never (79.8%) tobacco users. Similarly, other modes of marijuana use were significantly higher in current and former tobacco users compared to never tobacco users. Conclusions: Prevalence of all modes of ever marijuana use was higher in current and former tobacco users. These findings underscore the importance of considering the relationship between marijuana and tobacco use when developing programs and policies aimed at preventing and reducing marijuana use. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
18. Clinical interventions to reduce secondhand smoke exposure among pregnant women: a systematic review.
- Author
-
Van T. Tong, Dietz, Patricia M., Rolle, Italia V., Kennedy, Sara M., Thomas, William, and England, Lucinda J.
- Subjects
PASSIVE smoking ,CINAHL database ,CONFIDENCE intervals ,COUNSELING ,INFORMATION storage & retrieval systems ,MEDICAL databases ,PSYCHOLOGY information storage & retrieval systems ,MEDLINE ,HEALTH outcome assessment ,PATIENT education ,PRENATAL care ,RESEARCH funding ,SYSTEMATIC reviews ,RESEARCH bias ,DESCRIPTIVE statistics ,ODDS ratio ,PREGNANCY ,PREVENTION - Abstract
Objective To conduct a systematic review of clinical interventions to reduce secondhand smoke (SHS) exposure among non-smoking pregnant women. Data sources We searched 16 databases for publications from 1990 to January 2013, with no language restrictions. Study selection Papers were included if they met the following criteria: (1) the study population included non-smoking pregnant women exposed to SHS, (2) the clinical interventions were intended to reduce SHS exposure at home, (3) the study included a control group and (4) outcomes included either reduced SHS exposure of non-smoking pregnant women at home or quit rates among smoking partners during the pregnancy of the woman. Data extraction Two coders independently reviewed each abstract or full text to identify eligible papers. Two abstractors independently coded papers based on US Preventive Services Task Force criteria for study quality (good, fair, poor), and studies without biochemically-verified outcome measures were considered poor quality. Data synthesis From 4670 papers, we identified five studies that met our inclusion criteria: four focused on reducing SHS exposure among non-smoking pregnant women, and one focused on providing cessation support for smoking partners of pregnant women. All were randomised controlled trials, and all reported positive findings. Three studies were judged poor quality because outcome measures were not biochemically-verified, and two were considered fair quality. Conclusions Clinical interventions delivered in prenatal care settings appear to reduce SHS exposure, but study weaknesses limit our ability to draw firm conclusions. More rigorous studies, using biochemical validation, are needed to identify strategies for reducing SHS exposure in pregnant women. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
19. Tobacco Use among Middle & High School Students.
- Author
-
Arrazola, René A., Neff, Linda J., Kennedy, Sara M., Holder-Hayes, Enver, and Jones, Christopher D.
- Published
- 2014
- Full Text
- View/download PDF
20. Annual Healthcare Spending Attributable to Cigarette Smoking: An Update.
- Author
-
Xu, Xin, Bishop, Ellen E., Kennedy, Sara M., Simpson, Sean A., and Pechacek, Terry F.
- Subjects
- *
MEDICAL care research , *SMOKING prevention , *DISEASE prevalence , *PHYSIOLOGICAL effects of tobacco , *EPIDEMICS , *MEDICAID - Abstract
Background Fifty years after the first Surgeon General’s report, tobacco use remains the nation’s leading preventable cause of death and disease, despite declines in adult cigarette smoking prevalence. Smoking-attributable healthcare spending is an important part of overall smoking-attributable costs in the U.S. Purpose To update annual smoking-attributable healthcare spending in the U.S. and provide smoking-attributable healthcare spending estimates by payer (e.g., Medicare, Medicaid, private insurance) or type of medical services. Methods Analyses used data from the 2006–2010 Medical Expenditure Panel Survey linked to the 2004–2009 National Health Interview Survey. Estimates from two-part models were combined to predict the share of annual healthcare spending that could be attributable to cigarette smoking. The analysis was conducted in 2013. Results By 2010, 8.7% (95% CI=6.8%, 11.2%) of annual healthcare spending in the U.S. could be attributed to cigarette smoking, amounting to as much as $170 billion per year. More than 60% of the attributable spending was paid by public programs, including Medicare, other federally sponsored programs, or Medicaid. Conclusions These findings indicate that comprehensive tobacco control programs and policies are still needed to continue progress toward ending the tobacco epidemic in the U.S. 50 years after the release of the first Surgeon General’s report on smoking and health. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
21. Patterns of E-cigarette Use Frequency-National Adult Tobacco Survey, 2012-2014.
- Author
-
Sharapova, Saida R., Singh, Tushar, Agaku, Israel T., Kennedy, Sara M., and King, Brian A.
- Subjects
- *
ELECTRONIC cigarettes , *TOBACCO products , *ADULTS , *HEALTH surveys , *SEXUAL orientation , *SUBSTANCE abuse , *COMPARATIVE studies , *HEALTH behavior , *RESEARCH methodology , *MEDICAL cooperation , *RESEARCH , *RESEARCH funding , *SMOKING cessation , *TOBACCO , *EVALUATION research - Abstract
Introduction: Accounting for occasional or intermittent e-cigarette use has yielded higher estimates of current use among U.S. adults. However, frequency of e-cigarette use by population subgroups is not well described. This study assessed e-cigarette use frequency by sociodemographic characteristics and other tobacco product use among U.S. adults.Methods: This study analyzed combined data from the 2012-2013 (n=60,192) and 2013-2014 (n=75,233) National Adult Tobacco Survey, a telephone-based survey of U.S. adults aged ≥18 years, to assess frequency of e-cigarette use (daily, some days, rarely) by sex, age, race/ethnicity, education, annual household income, U.S. region, marital status, sexual orientation, and cigarette smoking and other tobacco product use (cigars, cigarillos, little filtered cigars; traditional pipes; water pipes; and chewing tobacco, snuff, dip, snus, and dissolvable tobacco products). Analyses took place in 2016.Results: Among current e-cigarette users, 19.3% used daily, 29.3% used some days, and 51.4% used rarely. Daily use was lowest among younger adults, Hispanics, and those who were single, never married, or not living with a partner; and greatest among non-Hispanic Asians (p<0.0001). Among current e-cigarette users, 25.3% were cigarette-only smokers, 52.8% smoked cigarettes and used other tobacco products, 5.5% used other tobacco products only, 6.5% were former cigarette-only smokers, 6.7% were former users of cigarettes and other tobacco products, 1.3% were former other tobacco product users only, and 1.8% never used cigarettes or other tobacco products.Conclusions: E-cigarette use frequency varies by sociodemographic characteristics and other tobacco use. Further surveillance, particularly related to frequency of e-cigarette use and its impact on cigarette cessation, could inform public health policy, planning, and practice. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.